Apoquel is not for humans. It is approved exclusively for use in dogs, has never been tested in human clinical trials, and its manufacturer explicitly states on the label: “This product is not for human use.” That said, the drug works through the same biological mechanism as several medications that are approved for people, which is likely why the question comes up so often.
Why Apoquel Only Exists for Dogs
Apoquel’s active ingredient, oclacitinib, belongs to a class of drugs called JAK inhibitors. These drugs block specific enzymes (Janus kinases) that drive inflammation and itching. Oclacitinib is particularly potent against JAK1, the enzyme most involved in allergic itch signaling, with roughly 10 times more activity against JAK1 than JAK3.
Here’s where it gets interesting: the JAK enzymes in dogs and humans are nearly identical. The sequence similarity between canine and human JAK1 is 98%, and for JAK3 it’s 100%. Some of the original lab testing for oclacitinib was actually done using human cell models because the enzymes are so closely matched. Despite this biological overlap, oclacitinib was developed and commercialized solely as a veterinary product by Zoetis, an animal health company. It has never been put through human safety trials, and no published research documents its effects when taken by a person.
Handling Risks for Pet Owners
The FDA-approved label for Apoquel includes specific human safety warnings that go beyond the usual “keep out of reach of children” language. Oclacitinib is classified as a hazardous drug. The manufacturer recommends wearing gloves when handling the tablets and washing your hands immediately afterward. People who are pregnant or nursing should not handle the medication at all.
If the tablet contacts your eyes, the label advises flushing with water or saline for at least 15 minutes and then getting medical attention. If someone accidentally swallows a tablet, the guidance is to seek medical attention immediately. Poison Control notes that there is no antidote for oclacitinib, which makes accidental ingestion a situation worth taking seriously. You can reach Poison Control at 1-800-222-1222 if this happens.
Human JAK Inhibitors That Work Similarly
If you’re asking about Apoquel for humans because you or someone you know has eczema, psoriasis, or another inflammatory skin condition, the good news is that several JAK inhibitors are already FDA-approved for people. They work through the same basic mechanism as Apoquel, blocking the JAK enzymes that fuel inflammation and itch, but they’ve been through rigorous human clinical trials with established safety profiles and dosing guidelines.
For moderate to severe eczema in adults, two oral options exist: abrocitinib (Cibinqo) and upadacitinib (Rinvoq), both taken once daily. Upadacitinib is also approved for children 12 and older who weigh at least 88 pounds. For milder eczema, a topical cream called ruxolitinib (Opzelura) is approved for adults and children 12 and up. That same cream is also approved for treating vitiligo.
Other conditions covered by human JAK inhibitors include severe alopecia areata (with three approved oral options: baricitinib, deuruxolitinib, and ritlecitinib) and psoriatic arthritis (treated with tofacitinib or upadacitinib). The range of approved uses continues to expand as more of these drugs complete clinical testing.
Why You Can’t Just Substitute One for the Other
Even though the underlying biology is similar between species, a drug approved for dogs can’t simply be swapped into human use. Veterinary drugs are formulated for canine metabolism, which processes compounds at different rates than the human body. The dosing, the inactive ingredients, the safety margins, and the potential for drug interactions are all calibrated for a different species. Without human pharmacokinetic data, there’s no way to know what a “safe” dose would be for a person, what side effects might emerge, or how the drug would interact with other medications.
JAK inhibitors as a class carry real risks even in their human-approved forms, including increased susceptibility to infections and, with long-term use, potential concerns about blood clots and certain cancers. These risks are carefully monitored and managed when a doctor prescribes a human JAK inhibitor at a known dose. Taking an unregulated veterinary version removes all of those safeguards.